What Antharis Therapeutics does

Antharis Therapeutics, Inc. is a privately held, pre-clinical to early clinical-stage biopharmaceutical company founded in 2020 by Dr. Raphael Ribeiro-Pinaud and headquartered in San Diego, California. The company develops antibody-based therapeutics — specifically monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs) — targeting oncology and other unmet medical needs, with a lead ADC program aimed at gastrointestinal cancers. Antharis also expanded into infectious and inflammatory disease biotherapies via its 2022 acquisition of Cassyni Biopharma.

The company's core technology platform uses large-scale unbiased screening, DNA-based immunization strategies, and proprietary antibody engineering to identify therapeutically-relevant targets and to produce monoclonal antibodies at success rates and scale that the company characterizes as exceeding industry norms. Through its June 2026 exclusive license from Lonza, Antharis added site-specific dual-payload ADC technology designed to deliver two therapeutic agents per antibody, addressing tumor heterogeneity and drug resistance. Manufacturing capability was added through the August 2023 acquisition of Galileo Biotech, which brought a GMP-certified production facility in Rio de Janeiro, Brazil, making Antharis a multinational. Five most advanced assets are expected to enter clinical trials in 2025.

The business model is pre-revenue and built around internal development plus selective licensing and partnerships. Antharis retains full responsibility for research, clinical development, manufacturing, and commercialization of its programs, while licensing in complementary platform technologies (e.g., Lonza ADC payload/linker manufacturing in exchange for upfront, milestone, and royalty payments). Future revenue is expected from product sales upon regulatory approval and from licensing/royalty streams. Customers are not yet defined commercially; the GTM motion targets pharmaceutical partners and large biotechs for co-development and licensing, with potential direct commercialization via specialty sales forces upon approval.

Name

Antharis Therapeutics

Legal name

Antharis Therapeutics, Inc.

Website

https://antharistherapeutics.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Antharis Therapeutics is a pre-clinical biopharmaceutical company developing monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates for oncology and other unmet medical needs, with a lead ADC program targeting gastrointestinal cancers and a GMP-certified manufacturing footprint in the US and Brazil.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Oncology therapeutics
• Monoclonal antibodies
• Antibody-drug conjugates
• Immuno-oncology
• Biopharmaceutical development

Headquarters

HQ city

Vista

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Others

Revenue model

1. ADC Licensing and Royalties: Antharis retains full responsibility for research, clinical development, manufacturing and commercialization of its ADC programs, while Lonza manufactures proprietary payload and linker components and is eligible for upfront, milestone, and royalty payments on net sales. This reflects a model where the company develops and commercializes proprietary biotherapeutic assets internally while licensing in complementary technology platforms.
2. Biopharmaceutical Asset Development and Commercialization: As a pre-clinical to clinical-stage biopharma, Antharis develops and plans to commercialize monoclonal antibody, bispecific antibody, and ADC therapeutic assets for oncology and other unmet medical needs. Revenue would derive from product sales following regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Antharis Therapeutics is a pre-clinical to clinical-stage biopharmaceutical company that discovers and develops antibody-based immunotherapies—primarily monoclonal antibodies (mAbs), bispecific antibodies, and antibody-drug conjugates (ADCs)—for oncology and other unmet medical needs. The company operates a proprietary antibody discovery platform using large-scale unbiased screening and DNA-based immunization to identify therapeutically-relevant targets, and it also develops next-generation dual-payload ADCs through an exclusive license from Lonza targeting gastrointestinal cancers.

Product overview

Antharis Therapeutics is a biopharmaceutical company that has developed a robust platform for discovering and developing antibody-based therapeutics. The company's product portfolio comprises three core therapeutic modalities: Monoclonal Antibodies (mAbs), Antibody-Drug Conjugates (ADCs), and Bispecific Antibodies. The portfolio also includes Dual-Payload ADCs developed through an exclusive licensing partnership with Lonza. These therapies are designed to harness the power of the immune system to combat cancer and other unmet medical needs. Antharis has one of the most extensive and diversified preclinical portfolios in the industry, with five most advanced assets expected to enter clinical trials in 2025.

Differentiator

Problem solved

Functional benefit

Products and services

• Monoclonal Antibodies (mAbs)

Quantifiable outcome

• Successfully completed two major M&A transactions (Cassyni Biopharma 2022, Galileo Biotech 2023), more than doubled portfolio of assets
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Lonza GroupcoreTechnology or Integration · 15 June 2026Antharis entered an exclusive, target-specific licensing agreement with Lonza to develop dual-payload antibody-drug conjugates targeting gastrointestinal cancers. Antharis gains rights to Lonza's clinically validated, site-specific ADC technology platform and will integrate it with its proprietary antibody engineering and target biology capabilities. Antharis retains full responsibility for research, clinical development, manufacturing, and commercialization, while Lonza manufactures proprietary payload and linker components and is eligible for upfront, milestone, and royalty payments on net sales.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• ADC Therapeutics: Clinical and commercial-stage ADC developer with approved products (Zynlonta). Closely comparable to Antharis in modality (ADCs) and oncology focus, though at a later stage and with greater pipeline focus on hematologic cancers.
• Ambrx Biopharma: Engineered antibody and ADC platform company with site-specific conjugation technology. Highly comparable to Antharis: Antharis' CTOO Ying Buechler was CTO at Ambrx and CSO Jim Xia was Principal Scientist there, indicating overlapping technology and team pedigree.
• Innovent Biologics: Commercial-stage biopharmaceutical developing monoclonal antibodies, bispecifics, and ADCs (e.g., with Eli Lilly partnerships). Comparable in therapeutic modalities — mAbs, bispecifics, ADCs — and oncology focus, though larger and commercially active.
• Mersana Therapeutics: Clinical-stage ADC developer with proprietary platforms (Dolasynthen, Immunosynthen). Directly comparable to Antharis as an oncology-focused ADC platform company at a similar development stage.

Broad incumbents

• ImmunoGen (AbbVie): Pioneer in ADCs (Kadcyla/Enhertu royalty stream), now part of AbbVie. Operates broadly in the same ADC and oncology biologics space as Antharis but at vastly greater scale and with approved products.
• Daiichi Sankyo: Global ADC market leader with Enhertu and Datroway partnered with AstraZeneca. A broad incumbent that defines the standard Antharis must compete against in dual-payload and next-generation ADC development.
• Seagen (Pfizer): Pioneer in ADC technology (Adcetris, Padcev, Tukysa); now a Pfizer subsidiary. Sets the bar for ADC development and represents both a potential acquirer/partner and a primary competitive threat for Antharis' oncology pipeline.

Emerging players

• Tubulis: European biotech developing next-generation ADCs with proprietary payload-linker and conjugation technologies. Directly comparable emerging peer in ADC platform development with overlapping technology goals around tumor-selective delivery.
• Bolt Biotherapeutics: Clinical-stage developer of immune-stimulating antibody conjugates (ISACs), a next-generation ADC approach. Comparable emerging player focused on antibody-based cancer therapeutics that harness immune system engagement, similar to Antharis' immune-harnessing paradigm.
• Pyxis Oncology: Clinical-stage biopharmaceutical developing ADC and immuno-oncology therapeutics. Comparable emerging ADC peer with overlapping oncology focus and similar platform-based approach to antibody-targeted cancer therapies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/antharis-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Antharis Therapeutics